Noninvasive quantification of pancreatic fat in humans

Ildiko Lingvay, Victoria Esser, Jaime L. Legendre, Angela L Price, Kristen M. Wertz, Beverley A Huet, Song Zhang, Roger H Unger, Lidia S. Szczepaniak

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Objective: To validate magnetic resonance spectroscopy (MRS) as a tool for non-invasive quantification of pancreatic triglyceride (TG) content and to measure the pancreatic TG content in a diverse human population with a wide range of body mass index (BMI) and glucose control. Methods: To validate the MRS method, we measured TG content in the pancreatic tissue of 12 lean and 12 fatty ZDF rats (ages5-14weeks) both by MRS and the gold standard biochemical assay. We used MRS to measure pancreatic TG content in vivo in 79 human volunteers. Additionally, to assess the reproducibility of the method, in 33 volunteers we obtained duplicate MRS measurements 1-2 weeks apart. Results: MRS quantifies pancreatic TG content with high reproducibility and concordance to the biochemical measurement (Spearman's rank correlation coefficient = 0.91). In humans, median pancreatic TG content was as follows: (1) normal weight and normoglycemic group 0.46 f/w%, (2) overweight or obese but normoglycemic group 3.16 f/w%, (3) impaired fasting glucose or impaired glucose tolerance group (BMI matched with group 2) 5.64 f/w%, and (4) untreated type 2 diabetes group (BMI matched with group 2) 5.54f/w% (Jonckheere-Terpstra trend test across groups p<0.001). Conclusions: Human pancreatic steatosis, as measured by MRS, increases with BMI and with impaired glycemia. MRS is a quantitative and reproducible non-invasive clinical research tool which will enable systematic studies of the relationship between ectopic fat accumulation in the pancreas and development of type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)4070-4076
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume94
Issue number10
DOIs
StatePublished - 2009

Fingerprint

Magnetic resonance spectroscopy
Magnetic Resonance Spectroscopy
Fats
Triglycerides
Body Mass Index
Medical problems
Glucose
Type 2 Diabetes Mellitus
Volunteers
Research Design
Glucose Intolerance
Nonparametric Statistics
Rats
Pancreas
Assays
Fasting
Tissue
Weights and Measures

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Noninvasive quantification of pancreatic fat in humans. / Lingvay, Ildiko; Esser, Victoria; Legendre, Jaime L.; Price, Angela L; Wertz, Kristen M.; Huet, Beverley A; Zhang, Song; Unger, Roger H; Szczepaniak, Lidia S.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 94, No. 10, 2009, p. 4070-4076.

Research output: Contribution to journalArticle

Lingvay, Ildiko ; Esser, Victoria ; Legendre, Jaime L. ; Price, Angela L ; Wertz, Kristen M. ; Huet, Beverley A ; Zhang, Song ; Unger, Roger H ; Szczepaniak, Lidia S. / Noninvasive quantification of pancreatic fat in humans. In: Journal of Clinical Endocrinology and Metabolism. 2009 ; Vol. 94, No. 10. pp. 4070-4076.
@article{e08210af47d2452fb8df4deb5a6ec4af,
title = "Noninvasive quantification of pancreatic fat in humans",
abstract = "Objective: To validate magnetic resonance spectroscopy (MRS) as a tool for non-invasive quantification of pancreatic triglyceride (TG) content and to measure the pancreatic TG content in a diverse human population with a wide range of body mass index (BMI) and glucose control. Methods: To validate the MRS method, we measured TG content in the pancreatic tissue of 12 lean and 12 fatty ZDF rats (ages5-14weeks) both by MRS and the gold standard biochemical assay. We used MRS to measure pancreatic TG content in vivo in 79 human volunteers. Additionally, to assess the reproducibility of the method, in 33 volunteers we obtained duplicate MRS measurements 1-2 weeks apart. Results: MRS quantifies pancreatic TG content with high reproducibility and concordance to the biochemical measurement (Spearman's rank correlation coefficient = 0.91). In humans, median pancreatic TG content was as follows: (1) normal weight and normoglycemic group 0.46 f/w{\%}, (2) overweight or obese but normoglycemic group 3.16 f/w{\%}, (3) impaired fasting glucose or impaired glucose tolerance group (BMI matched with group 2) 5.64 f/w{\%}, and (4) untreated type 2 diabetes group (BMI matched with group 2) 5.54f/w{\%} (Jonckheere-Terpstra trend test across groups p<0.001). Conclusions: Human pancreatic steatosis, as measured by MRS, increases with BMI and with impaired glycemia. MRS is a quantitative and reproducible non-invasive clinical research tool which will enable systematic studies of the relationship between ectopic fat accumulation in the pancreas and development of type 2 diabetes.",
author = "Ildiko Lingvay and Victoria Esser and Legendre, {Jaime L.} and Price, {Angela L} and Wertz, {Kristen M.} and Huet, {Beverley A} and Song Zhang and Unger, {Roger H} and Szczepaniak, {Lidia S.}",
year = "2009",
doi = "10.1210/jc.2009-0584",
language = "English (US)",
volume = "94",
pages = "4070--4076",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Noninvasive quantification of pancreatic fat in humans

AU - Lingvay, Ildiko

AU - Esser, Victoria

AU - Legendre, Jaime L.

AU - Price, Angela L

AU - Wertz, Kristen M.

AU - Huet, Beverley A

AU - Zhang, Song

AU - Unger, Roger H

AU - Szczepaniak, Lidia S.

PY - 2009

Y1 - 2009

N2 - Objective: To validate magnetic resonance spectroscopy (MRS) as a tool for non-invasive quantification of pancreatic triglyceride (TG) content and to measure the pancreatic TG content in a diverse human population with a wide range of body mass index (BMI) and glucose control. Methods: To validate the MRS method, we measured TG content in the pancreatic tissue of 12 lean and 12 fatty ZDF rats (ages5-14weeks) both by MRS and the gold standard biochemical assay. We used MRS to measure pancreatic TG content in vivo in 79 human volunteers. Additionally, to assess the reproducibility of the method, in 33 volunteers we obtained duplicate MRS measurements 1-2 weeks apart. Results: MRS quantifies pancreatic TG content with high reproducibility and concordance to the biochemical measurement (Spearman's rank correlation coefficient = 0.91). In humans, median pancreatic TG content was as follows: (1) normal weight and normoglycemic group 0.46 f/w%, (2) overweight or obese but normoglycemic group 3.16 f/w%, (3) impaired fasting glucose or impaired glucose tolerance group (BMI matched with group 2) 5.64 f/w%, and (4) untreated type 2 diabetes group (BMI matched with group 2) 5.54f/w% (Jonckheere-Terpstra trend test across groups p<0.001). Conclusions: Human pancreatic steatosis, as measured by MRS, increases with BMI and with impaired glycemia. MRS is a quantitative and reproducible non-invasive clinical research tool which will enable systematic studies of the relationship between ectopic fat accumulation in the pancreas and development of type 2 diabetes.

AB - Objective: To validate magnetic resonance spectroscopy (MRS) as a tool for non-invasive quantification of pancreatic triglyceride (TG) content and to measure the pancreatic TG content in a diverse human population with a wide range of body mass index (BMI) and glucose control. Methods: To validate the MRS method, we measured TG content in the pancreatic tissue of 12 lean and 12 fatty ZDF rats (ages5-14weeks) both by MRS and the gold standard biochemical assay. We used MRS to measure pancreatic TG content in vivo in 79 human volunteers. Additionally, to assess the reproducibility of the method, in 33 volunteers we obtained duplicate MRS measurements 1-2 weeks apart. Results: MRS quantifies pancreatic TG content with high reproducibility and concordance to the biochemical measurement (Spearman's rank correlation coefficient = 0.91). In humans, median pancreatic TG content was as follows: (1) normal weight and normoglycemic group 0.46 f/w%, (2) overweight or obese but normoglycemic group 3.16 f/w%, (3) impaired fasting glucose or impaired glucose tolerance group (BMI matched with group 2) 5.64 f/w%, and (4) untreated type 2 diabetes group (BMI matched with group 2) 5.54f/w% (Jonckheere-Terpstra trend test across groups p<0.001). Conclusions: Human pancreatic steatosis, as measured by MRS, increases with BMI and with impaired glycemia. MRS is a quantitative and reproducible non-invasive clinical research tool which will enable systematic studies of the relationship between ectopic fat accumulation in the pancreas and development of type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=70349929485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349929485&partnerID=8YFLogxK

U2 - 10.1210/jc.2009-0584

DO - 10.1210/jc.2009-0584

M3 - Article

VL - 94

SP - 4070

EP - 4076

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 10

ER -